activ
somat
mutat
confer
sensit
epiderm
growth
factor
receptor
egfr
tyrosin
kinas
inhibitor
wide
use
develop
advanc
metastat
primari
lung
cancer
therapi
therefor
identif
egfr
mutat
essenti
present
studi
loopmedi
isotherm
amplif
lamp
method
use
identifi
egfr
mutat
effici
compar
therascreen
quantit
pcr
assay
use
lamp
therascreen
analyz
surgic
resect
tissu
sampl
patient
pulmonari
adenocarcinoma
egfr
mutat
observ
tumor
sampl
lamp
tumor
sampl
therascreen
notabl
lamp
assay
identifi
one
tumor
wildtyp
previous
identifi
delet
mutat
exon
via
therascreen
assay
case
x
howev
direct
sequenc
confirm
egfr
statu
case
x
adher
result
lamp
assay
experi
use
case
x
dna
identifi
exon
delet
mutat
use
method
addit
novel
delet
mutat
exon
egfr
identifi
overal
present
studi
show
lamp
method
may
serv
valuabl
altern
identif
oncogen
mutat
lung
cancer
highest
morbid
mortal
malign
usa
nonsmal
cell
lung
carcinoma
nsclc
common
form
lung
cancer
account
case
primarili
treat
use
system
chemotherapi
howev
nsclc
treatment
evolv
due
develop
therapi
target
activ
mutat
epiderm
growth
factor
receptor
egfr
egfr
activ
caus
genet
mutat
confer
suscept
egfr
tyrosin
kinas
inhibitor
tki
treatment
first
report
egfr
mutat
pulmonari
adenocarcinoma
present
caucasian
popul
east
asian
popul
clinic
trial
shown
patient
pulmonari
adenocarcinoma
egfr
mutat
exhibit
clinic
respons
oral
administ
egfr
inhibitor
lin
et
al
report
patient
egfrmut
metastat
lung
adenocarcinoma
surviv
time
therefor
detect
egfr
mutat
import
step
treatmentdecis
pathway
patient
pulmonari
adenocarcinoma
previous
direct
dna
sequenc
standard
method
detect
genet
mutat
howev
present
sever
altern
method
mutat
test
develop
exampl
therascreen
egfr
pcr
kit
qiagen
inc
commerci
quantit
q
pcr
kit
wide
adopt
clinic
practic
howev
method
timeconsum
possess
certain
procedur
complex
exampl
requir
sever
temperatur
chang
dna
amplif
nextgener
sequenc
improv
effici
oncogen
test
highthroughput
sequenc
detect
dozen
mutat
time
highcost
techniqu
limit
clinic
usag
therefor
detect
oncogen
mutat
use
simpl
easi
highli
reproduc
method
remain
challeng
loopmedi
isotherm
amplif
lamp
new
pcr
base
method
high
level
specif
novel
loopmedi
isotherm
amplif
method
effici
robust
detect
egfr
mutat
amplif
effici
util
six
primer
method
perform
isotherm
condit
therebi
enabl
rapid
amplif
due
high
specif
rapid
detect
qualiti
lamp
method
wide
use
field
bacteriolog
virolog
howev
best
knowledg
studi
report
valu
lamp
determin
egfr
mutat
therefor
present
studi
aim
detect
egfr
mutat
surgic
resect
tumor
tissu
patient
pulmonari
adenocarcinoma
use
method
detect
egfr
mutat
one
key
examin
patient
pulmonari
adenocarcinoma
addit
sensit
specif
posit
predict
valu
neg
predict
valu
accuraci
lamp
evalu
compar
therascreen
egfr
pcr
kit
tumor
tissu
sampl
tumor
tissu
surgic
resect
consecut
patient
diagnos
pulmonari
adenocarcinoma
expert
pathologist
saitama
cardiovascular
respiratori
center
kumagaya
japan
januari
octob
patholog
diagnosi
determin
basi
classif
version
expert
pathologist
normal
make
diagnosi
use
hestain
slide
use
light
microscop
nikon
co
eclips
niu
low
magnif
high
magnif
inclus
criteria
follow
surgic
resect
tissu
primari
lung
cancer
ii
pulmonari
adenocarcinoma
iii
enough
volum
materi
molecular
test
iv
inform
written
consent
patient
convers
case
inform
consent
less
volum
sampl
exclud
clinic
characterist
patient
present
tabl
mean
patient
age
year
includ
male
femal
sampl
fix
buffer
formalin
room
temperatur
h
creat
formalinfix
paraffinembed
ffpe
tumor
block
depart
patholog
saitama
cardiovascular
respiratori
center
hematoxylineosin
stain
perform
standard
method
use
tissuetek
prisma
sakura
finetek
japan
co
ltd
accord
manufactur
protocol
prior
dna
extract
tumor
content
sampl
assess
use
light
microscopi
magnif
ensur
effici
pcr
amplif
section
deparaffin
xylen
hydrat
grade
seri
ethanol
ethanol
dna
tissu
block
extract
use
qiaamptm
dna
ffpe
tissu
kit
qiagen
inc
analyz
use
qiacub
robot
qiagen
inc
accord
manufactur
protocol
therascreen
qpcr
mutat
analysi
presenc
egfr
mutat
determin
use
therascreen
egfr
pcr
kit
qiagen
inc
accord
manufactur
protocol
primer
design
primer
set
lamp
amplif
partial
sequenc
egfr
gene
design
use
primer
explor
primerexplorerjp
fig
present
sequenc
primer
use
forward
backward
outer
primer
forward
backward
inner
primer
fip
bip
forward
backloop
primer
lf
lb
primer
synthes
purifi
eurofin
genom
block
oligo
fluorophorelabel
probe
synthes
purifi
japan
bio
servic
co
ltd
gene
design
inc
tabl
ii
lamp
egfr
mutat
analysi
lamp
assay
detect
egfr
wild
type
egfr
mutat
tabl
ii
among
egfr
mutat
exon
point
mutat
exon
delet
simultan
exon
point
mutationexon
point
mutat
exon
point
mutat
alon
identifi
tabl
ii
concentr
egfr
mutat
detect
dna
sampl
therascreen
assay
tabl
si
hand
minimum
concentr
lamp
assay
sinc
lamp
assay
demonstr
one
success
detect
per
test
level
concentr
posit
per
test
concentr
tabl
si
direct
sequenc
case
x
observ
singl
case
deviat
identif
mutat
exon
therascreen
pcr
lamp
assay
confirm
result
direct
sequenc
target
site
exon
perform
direct
sequenc
result
demonstr
mutat
exon
case
x
concord
result
lamp
assay
reconfirm
statu
egfr
mutat
case
x
four
addit
ffpe
tissu
block
case
x
use
extract
dna
sampl
hematoxylineosin
imag
ffpe
block
present
fig
follow
remov
normal
lung
tissu
dna
sampl
extract
aforement
investig
use
therascreen
egfr
pcr
lamp
assay
four
sampl
delet
mutat
exon
identifi
use
therascreen
pcr
lamp
assay
furthermor
direct
sequenc
reveal
novel
exon
egfr
delet
mutat
sampl
b
repres
delet
nucleotid
attaagagaagcaacatc
data
shown
replac
gca
nucleotid
triplet
chang
ggaattaagagaagcaacatctcc
ggagcatcc
data
shown
result
shorten
substat
protein
egfr
mutat
pulmonari
adenocarcinoma
associ
sensit
tki
therapi
henc
identif
egfr
mutat
becom
standard
analysi
treatment
pathway
patient
pulmonari
adenocarcinoma
although
number
method
avail
standard
approach
satisfi
practic
clinic
requir
simplic
rapid
cheap
sever
pcr
base
method
previous
use
routin
test
detect
egfr
statu
unit
state
european
union
japan
china
includ
scorpion
amplif
refractori
mutat
system
arm
therascreen
pcr
assay
method
approv
fda
standard
approach
egfr
gene
analysi
lung
cancer
fda
govmedicaldevicesrecentlyapproveddevicestherascreenrfg
howev
although
stabl
reliabl
approach
procedur
complex
includ
complex
set
control
temperatur
sever
time
use
cycleav
develop
japan
commerci
use
central
laboratori
sensit
pnalna
pcr
clamp
specif
accuraci
cycleav
pcr
result
lamp
new
pcr
method
consid
robust
approach
gene
analysi
requir
sophist
expens
equip
thermal
cycler
necessari
pcr
therefor
lamp
method
may
potenti
decreas
cost
gene
analysi
previou
studi
demonstr
valu
lamp
field
bacteriolog
virolog
howev
studi
report
valu
lamp
oncolog
ikeda
et
al
use
lamp
assay
detect
egfr
mutat
nsclc
demonstr
valu
lamp
mutat
studi
therefor
present
studi
aim
investig
egfr
mutat
includ
exon
exon
minor
mutat
use
lamp
assay
sensit
specif
ppv
npv
accuraci
valu
lamp
egfr
mutat
compar
therascreen
assay
method
respect
demonstr
potenti
lamp
effici
altern
approach
oncogen
mutat
analys
evalu
sensit
two
assay
genet
analysi
perform
investig
minimum
concentr
egfr
mutat
detect
method
minimum
concentr
lamp
detect
therascreen
assay
therefor
minimum
concentr
lamp
assay
time
higher
therascreen
assay
almost
equal
effici
detect
exon
mutat
case
x
use
therascreen
method
suggest
lamp
well
direct
sequenc
method
could
identifi
fals
neg
howev
addit
experi
investig
case
x
tumor
tissu
demonstr
presenc
delet
mutat
exon
direct
sequenc
method
report
low
sensit
wherea
therascreen
method
gener
recogn
promis
method
howev
identifi
mutat
simplifi
improv
faster
cheaper
method
identif
develop
clinic
applic
addit
case
x
experi
also
identifi
novel
egfr
mutat
use
direct
sequenc
identifi
use
therascreen
lamp
howev
mutat
may
detect
exon
delet
primer
similarli
target
mutat
howev
detail
primer
lamp
method
could
disclos
due
polici
eiken
co
ltd
inform
concern
primer
therascreen
egfr
pcr
kit
could
obtain
due
patent
furthermor
present
studi
note
novel
mutat
includ
cosmic
databas
previou
studi
report
mutat
therefor
present
studi
first
report
egfr
mutat
best
knowledg
conclus
lamp
method
may
valuabl
altern
identif
oncogen
mutat
lung
cancer
current
studi
group
develop
new
method
detect
oncogen
use
liquid
biopsi
data
shown
addit
novel
mutat
identifi
exon
egfr
howev
need
valid
clinic
use
present
studi
fund
eiken
chemic
co
ltd
dataset
use
andor
analyz
present
studi
avail
correspond
author
upon
reason
request
